期刊文献+

急性STEMI病人在PCI术不同时间应用替罗非班对即刻靶血管造影和心肌损伤的影响 被引量:11

The Infuence of Different Time Application of Tirofiban on the Immediate Targetangiography and Myocardial Injury in Patients with Acute ST-segment Elevation Myocardial Infarction undergoing Percutaneous Coronary Intervention
下载PDF
导出
摘要 目的探究急性ST段抬高型心肌梗死(STEMI)病人在经皮冠脉介入治疗(PCI)术不同时间应用替罗非班对即刻靶血管造影和心肌损伤的影响。方法选取2011年2月—2014年5月武汉大学人民医院行经皮冠脉介入治疗的急性ST段抬高型心肌梗死病人200例作为观察对象,按照替罗非班应用时机不同分为3组,在抢救室应用替罗非班治疗的95例病人作为观察A组,在导管室应用替罗非班治疗的56例病人作为研究B组,不使用替罗非班治疗,同时向冠脉内注射等量0.9%氯化钠注射液治疗的49例病人作为对照组,其余调脂、抗凝治疗方式均相同,采用TIMI血流及心肌灌注分级标准评价病人PCI治疗前后即刻靶血管造影情况,观察PCI前后心肌损伤标志物变化、PCI后主要不良心脏事件以及出血并发症和血小板减少症发生率。结果 3组病人在PCI前TIMI血流分级和心肌灌注分级差异无统计学意义(P>0.05),在PCI后,3组病人TIMI血流分级无变化(P>0.05),观察A组和观察B组在心肌灌注分级方面优于对照组(P<0.05);心肌损伤标志物方面,3组病人在PCI前磷酸肌酸激酶同工酶(CK-MB)、肌钙蛋白(c TNT)含量方面差异无统计学意义(P>0.05),在PCI后观察A组、观察B组CK-MB含量差异有统计学意义(P<0.05);3组病人随访半年,在出血并发症、血小板减少症、主要心血管事件(MACE)发生情况差异无统计学意义(P>0.05)。结论 STEMI病人行急诊PCI早期应用替罗非班治疗可以改善即刻梗死相关动脉的血流和心肌灌注,降低心肌损伤程度,并发症和不良反应可以耐受。 Objective To explore the effects of different time application of tirofiban on immediate targetangiography and myocardial injury in patients with acute ST-segment elevation myocardial infarction( STEMI) undergoing percutaneous coronary intervention( PCI). Methods Two hundreds patients with STEMI undergoing PCI were selected in our hospital from February 2011 to May 2014,in accordance with the different time application of tirofiban were divided into three groups,in the resuscitation room of tirofiban in patients with 95 cases as group A,the application of tirofiban therapy in patients with 56 cases as group B,without the use of tirofiban intracoronary injection of equal,at the same time to the 0. 9 % Sodium Chloride injection treatment in patients with 49 cases as the control group,the remaining lipid,anticoagulation therapy were the same. The immediate target of angiography was evaluated by thrombolysis in myocardial infarction( TIMI) blood flow and myocardial perfusion grading standards. The changes of biochemical markers of myocardial injury were observed before and after PCI. The major adverse cardiovascular events( MACE),bleeding complications and the incidence of thrombocytopenia were observed. Results There was no difference in the TIMI flow grade and PCI myocardial perfusion grade among three groups before PCI(P〉0. 05). After PCI,TIMI flow grades were unchanged in three groups(P〈0. 05). The myocardial perfusion grades in group A and group B were better than that in control group(P〈0. 05). There was no difference in the contents of CK-MB and c TNT among three groups before PCI(P〈0. 05). After PCI,There was a difference in the contents of CK-MB and c TNT among three groups(P〉0. 05). After follow-up for 6 months,There was no difference in the occurrence of bleeding,thrombocytopenia,MACE among three groups(P〉0. 05). Conclusion Early application of tirofiban in patients with STEMI undergoing emergency PCI can improve the immediate infarction related artery blood flow and myocardial perfusion,reduce the degree of myocardial injury,complications,and adverse reactions could be tolerated.
作者 邹行斌 黄鹤
出处 《中西医结合心脑血管病杂志》 2016年第22期2603-2606,共4页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 急性ST段抬高型心肌梗死 经皮冠脉介入治疗 替罗非班 血管造影 磷酸肌酸激酶同工酶 肌钙蛋白 acute ST-segment elevation myocardial infarction percutaneous coronary intervention tirofiban targetangiography creatine kinase MB isoenzyme cardiac troponin T
  • 相关文献

参考文献5

二级参考文献32

  • 1Razakjr OA,Tan HC,Yip WL,et al.Predictors of bleeding com-plications and thrombocytopenia with the use of abciximab duringpercutaneous corony intervention[J].J Interv Cardiol,2005,18(1):33-37.
  • 2Valgimigli M,Tebaldi M.Safety evaluation of tirofiban[J].ExpertOpin Drug Saf,2010,9(5):801-819.
  • 3Naruko T, Ueda M, Haze K,et al. Neutrophil infiltration of cuoprit lesions in acute coronary syndromes[ J]. Circulation, 2002, 106 ( 23 ) :2894-2900.
  • 4Azar R, Badaoui G, Sarkis A, et al. Effects of tirofiban and statins on high sensiitivity Creactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery dlsease[J]. Am J Cardiol, 2005, 95(2) :236-240.
  • 5Stone GW, Grines CL, Cox DA, et al. Comparision of angioplasty with stenting, with or without abciximab, in acute myocardial infarction[J]. N Eng J Med, 2002,346(13):957-966.
  • 6Fox KA,Poole-Wilson PA,Henderson RA,et al.Inter-ventional versus conservative treatment for patients withunstable angina or non-ST-segment elevation myocardialinfarction:the British Heart Foundation RITA 3random-ised trial[J].Lancet,2002,360(9335):743-751.
  • 7Brounwald E,Antman EM,Beasley JW,et al.ACC/AHA 2002guideline update for the management of pa-tients with unstable angina or non-ST-segment elevationmyocardial infarction:summary article:a report of theAmerican College of Cardiology/American Heart Associ-ation Task Force on Practice Guidelines[J].Circulation,2002,106:1893-1900.
  • 8Antman EM,Cohen M,Bernink PJ,et al.The TIMI riskscore for unstable angina/non-ST elevation MI:a methodfor prognostication and therapeutic decision making[J].JAMA,2000,284:835-842.
  • 9陈桂英,李为民.无复流现象及防治策略[M].李为民,霍勇,吕树铮.冠心病介入治疗策略与技巧.北京:人民卫生出版社,2007:57-69.
  • 10James C.Bleeding complications of glycoproteinⅡb∕Ⅲa receptor inhibitors[J].Am Heart J,1999,138:S287-294.

共引文献63

同被引文献88

引证文献11

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部